Dermatopontin CRISPR/Cas9 KO Plasmid (h): sc-402924
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- Dermatopontin CRISPR/Cas9 Knockout (KO) Plasmid (h) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the Dermatopontin genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: Dermatopontin Antibody (F-4): sc-376863
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Dermatopontin CRISPR/Cas9 KO Plasmid (h) | sc-402924 | 20 µg | $397.00 |
Overview
DPT encodes dermatopontin, a tyrosine-rich extracellular matrix protein that binds collagen and modulates matrix organization, cell adhesion, and cell–matrix signaling. Dermatopontin influences extracellular matrix assembly and remodeling by affecting collagen fibrillogenesis and interfacing with growth factor–regulated pathways, including TGF-β–associated responses that shape fibroblast activity. Altered DPT expression has been linked to fibrotic remodeling, wound healing dynamics, and stromal changes observed across multiple pathological contexts. As a stromal ECM component, dermatopontin is also relevant for studying how microenvironmental cues regulate cell migration, mechanotransduction, and tissue architecture.
Dermatopontin CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the DPT gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the DPT together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the DPT open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish Dermatopontin protein expression.
This CRISPR knockout system enables efficient generation of DPT-deficient cell models for investigation of Dermatopontin signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting DPT exon(s) critical for Dermatopontin function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple DPT genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by Dermatopontin CRISPR/Cas9 KO Plasmid (h) and Dermatopontin CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the DPT locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by Dermatopontin HDR Plasmid (h) and Dermatopontin HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by DPT homology arms to support homology-directed repair at defined DPT target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.